Navigation Links
Boehringer Ingelheim Invests More Than $350 Million in 2011 U.S. Expansion Projects
Date:11/15/2011

ness, Boehringer Ingelheim Vetmedica, Inc., this summer dedicated its new $89 million vaccine research facility in Sioux Center, Iowa, one of three special vaccine research buildings it will build there. The company also announced a $100 million expansion of its biological manufacturing facility in St. Joseph's, Missouri.

In September, Boehringer Ingelheim Roxane, Inc., opened a new $50 million High Containment Operations facility in Columbus, Ohio in order to meet a growing market demand for high potency and oncology products.  The building uses state-of-the-art technology to develop and manufacture differentiated high potency oral solid tablets and capsules in support of Roxane Laboratories', Inc. rapidly growing multisource business.  

In addition to these capital investments, Boehringer Ingelheim gained a presence on the West Coast with the acquisition in March of Boehringer Ingelheim Fremont, Inc. The facility, acquired from Amgen, manufactures biological medicines, and consists of more than 300,000 square feet for laboratories, manufacturing and process development suitable for clinical and market supplies.

"These are exciting projects; ones that increase Boehringer Ingelheim's research and development capabilities and reinforce our commitment to growth and innovation in the U.S.," said J. Martin Carroll, President and CEO of Boehringer Ingelheim's U.S. operations. "Through these investments we are improving our ability to research, develop and manufacture the medicines of tomorrow and in doing so fulfilling our promise to bring more health to patients and their families."

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturi
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheims Two Investigational HCV Direct Acting Antivirals Presented at AASLD
2. Boehringer Ingelheim and Lilly to Feature Type 2 Diabetes Research in Presentations at the 47th Annual Meeting of the European Association for the Study of Diabetes
3. Boehringer Ingelheim Broadens Its Breast Cancer Clinical Trial Program for the Investigational Compound Afatinib
4. Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves
5. Boehringer Ingelheim and Ashokas Changemakers Launch "Making More Health" Competition
6. Ashoka and Boehringer Ingelheim Announce a Global Partnership for "Making More Health"
7. Zealand Pharma and Boehringer Ingelheim Enter Into a Licence and Collaboration Agreement to Advance Novel Compounds to Treat Type-2 Diabetes and Obesity
8. Boehringer Ingelheim to present new data at ASCO annual meeting regarding its investigational compound afatinib in EGFR-mutation positive patients with advanced NSCLC
9. Positive Phase 2 Results Reported with Boehringer Ingelheims Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients
10. Pfenex Inc. and Boehringer Ingelheim Announce Non-Exclusive Strategic Agreement for the Use of Pfenex Expression Technology™
11. Boehringer Ingelheim to Purchase Amgens Fremont (USA) Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)...   InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or ... today announced that its CGuard TM Embolic Prevention System ... Piotr Musialek , at the EuroPCR conference ... . PARADIGM, an investigator-initiated P rospective evaluation ... D revascularization I n symptomatic and increased-risk asymptomatic ...
(Date:5/22/2015)... CITY, Calif. , May 22, 2015 ... pharmaceutical company focused on the development and commercialization of ... pain, today announced that interim chief executive officer ... Healthcare Conference and chief financial officer Tim Morris ... Conference. Details of the two presentations are as follows: ...
(Date:5/21/2015)... Research and Markets ( ... "Market Assessment of Respiratory Diagnostics in the ... offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,This research service ... market in the United States ... service provides detailed analysis of the current and ...
Breaking Medicine Technology:InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences In June 2United States and Europe Respiratory Diagnostics Market Assessment 2015 2
... Medicine the B.E.S.T,study conducted in Italy , “TAKEN ... CONTROLLED,SUCCESSFULLY” , Prof. Fabbri: “Daily drug useless for ... people”.,Chiesi’s commitment to pneumological research , MILAN, Italy, ... dose,of cortisone necessary for the control of mild ...
... is,accumulating that depression is a risk factor for ... Health Watch. A,recent study found that people ages ... serotonin reuptake inhibitors,(SSRIs) had double the rate of ... points to depression itself as a source,of endocrine ...
Cached Medicine Technology:Mild Asthma, a Revolutionary Therapy from Italian Research 2Mild Asthma, a Revolutionary Therapy from Italian Research 3Antidepressant Use May Boost Fracture Risk, From Harvard Women's,Health Watch 2
(Date:5/23/2015)... May 23, 2015 On May 16, the ... The event was a 5k mud obstacle run that raised ... 2 million people worldwide, and the reason we participated was ... Chad Davis, owner of Farrell’s eXtreme Bodyshaping. “One-hundred percent of ... Society.” , The event was not only attended by eXtreme ...
(Date:5/23/2015)... 23, 2015 Add High-Quality prismatic refractions into ... Studios. , It's as simple as dragging and dropping footage ... tool for full effect. , Including over 80 stunning ... 5k sensors making this the ultimate bundle for adding prismatic ... in this package are movie files designed for Final Cut ...
(Date:5/22/2015)... The American College of Traditional Chinese ... They will hold a webinar on the updates of ... on Classical Chinese Medicine. , Webinar – First Professional ... the Dean of Clinical Education, will lead this webinar ... Doctorate program. ACTCM is currently developing this degree program ...
(Date:5/22/2015)... Following yesterday’s announcement that Ascenta Health ... health brand Nature’s Way, Marc St-Onge has affirmed his ... Skin is an integral part of the agreement with ... to further develop Ascenta Skin into a leading player ... a breakthrough, anti-aging skincare supplement featuring 6 active ingredients ...
(Date:5/22/2015)... Topsfield, MA (PRWEB) May 22, 2015 ... Keri Hart, MS/CCC, SLP, RAC-CT, CHHRP-QT, Vice President ... International, “A very important ‘language’ that impacts how ... International, the leader in long term care reimbursement, ... and education programs and talent management, launches a ...
Breaking Medicine News(10 mins):Health News:Farrell’s eXtreme Bodyshaping Team Runs through the Muck for MS 2Health News:Developers at Pixel Film Studios Release ProFlare 5K Prism for Final Cut Pro X. 2Health News:ACTCM Announces Upcoming June Events 2Health News:Ascenta Skin President Announces Plans to Grow Brand 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 3
... Va.The Society of Interventional Radiology Foundation recently received ... future scholarship fund for interventional radiology fellows to ... to advancing the clinical needs of interventional radiology ... pivotal basic and clinical trials research. "This ...
... SEPTEMBER 23, 2009 Late-breaking data from SPIRIT IV, ... the U.S., shows that an everolimus-eluting stent demonstrated enhanced ... native coronary artery lesions when compared to a paclitaxel-eluting ... achieved with drug-eluting stents without sacrificing safety. ...
... Recent studies conducted by Dr. Eric Blough and his ... the common pain reliever acetaminophen may help prevent age-associated ... how acetaminophen may affect the regulation of protein kinase ... role in regulation of cellular survival, proliferation and metabolism. ...
... growth in key industries and stall already-weak GDP growth in ... economist in the University of Alabama at Birmingham (UAB) School ... in the economy of many U.S. cities and communities," Bryce ... the virus, consumers and businesses may respond by restricting travel ...
... ... External services for pharmaceutical firms have shown consistent growth ... to proliferate. The global share of biotechnology services spending is in ... The range of high-quality external services available to pharma ranges from ...
... thinking difficulties reported by breast cancer survivors, researchers say ... save the lives of people with cancer, but new ... brain. , Many cancer patients who receive chemotherapy ... loss of memory and the ability to concentrate, and ...
Cached Medicine News:Health News:Society of Interventional Radiology Foundation receives $1 million legacy gift 2Health News:SPIRIT IV trial shows everolimus stent sets new standard for event-free survival 2Health News:Research shows safe dosages of common pain reliever may help prevent conditions related to aging 2Health News:Swine flu could wreak more havoc on US economy, says UAB economist 2Health News:Cambridge Healthtech Institute and Bio-IT World Launch a New eNewsletter: Pharma Services News 2Health News:After-Effects of Chemotherapy May Include Memory Problems 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: